Kornimate/medical-research-clean huggingface dataset:
pre-discharge bundle for patients with acute exacerbations of chronic obstructive pulmonary disease to reduce readmissions

Conditions: Chronic Obstructive Pulmonary Disease; Exacerbation of Chronic Obstructive Pulmonary Disease

Summary: hospital readmissions for acute exacerbations of chronic obstructive pulmonary disease (aecopd) pose burdens to the healthcare system and patients. the aim of this study was to determine whether a screening and educational tool, administered prior to discharge, would result in a decrease in the rate of hospital readmissions.

hospital readmissions for acute exacerbations of chronic obstructive pulmonary disease (aecopd) pose burdens to the healthcare system and patients. a current gap in knowledge is whether a pre-discharge screening and educational tool, administered to patients with copd, reduces readmissions and emergency department (ed) visits. a single center, randomized trial of patients admitted with aecopd. patients will be randomized to control (standard care) or "bundle" group in which patients receive smoking cessation counseling, screening for gastroesophageal reflux disease and depression or anxiety, standardized inhaler teaching, and a 48-hour post-discharge phone call.

Eligibility criteria:
inclusion criteria: * diagnosis of copd with the presence of an aecopd * age \> 40 * current or ex-smoker with history of at least 20 pack-years exclusion criteria: * past history of asthma, interstitial lung disease, bronchiectasis, presence of airway hardware (e.g. tracheal stents or tracheotomy), lung cancer, any other cancer with a life expectancy of less than 1 year * presence of a language barrier * residence in a nursing home * intensive care unit stay during the current admission * delirium or dementia.

Keywords: chronic obstructive pulmonary disease copd readmissions
morphine, midazolam and dexmedetomidine in the management of acute cardiogenic pulmonary edema, safety and efficacy

Conditions: Sedative Adverse Reaction

Summary: acute cardiogenic pulmonary edema is a stressful scenario with progressive respiratory failure that may lead to cardiorespiratory collapse within hours, or minutes unless therapeutic action is taken as the initial events in involve hemodynamic pulmonary congestion with high capillary pressures, diuretics, non-invasive ventilation (niv) and vasodilators constitute the key armamentarium for the initial treatment.

the patients will be randomized in a 1:1:1 ratio, (group midazolam i) midazolam (administered intravenously at a dosage of 1 mg, up to a maximum dose of 3 mg) (group morphine) morphine (administered intravenously at a dosage of 2-4 mg, up to a maximum dose of 8 mg \[14\], \[15\],(group dexmedetomidine.) dexmedetomidine ( administered intravenously, load: 0.25 mcg/kg iv over 10 minutes , maintenance 0.2-0.7 mcg/kg/hr continuous iv infusion according to haemodynamics and sedation score of patient ; not to exceed 24 hr • boluses of morphine, midazolam and dexmeddetomidine will be repeated on demand according to ramsay sedation scale. • all patients will be assessed for need of noninvasive ventilation by total face mask connected to ventilator. • medical therapy with intravenous boluses of loop diuretics, intravenous infusions of nitroglycerine, oxygen supplementation will be provided by physicians according to their clinical judgment • the target in all patients is to provide anxiolytic or light sedation effect for good compliance to noninvasive ventilation and reducing of pulmonary congestion. • the expected sedation scores (ramsay score 2-3) will be achieved in all of the patients taking morphine, midazolam or dexmedetomidine

Eligibility criteria:
inclusion criteria: * age \>18 year with a clinical diagnosis of acpe with severe dyspnea and anxiety. * patients able to verbally acknowledge the risks in receiving midazolam, morphine or dexmedetomidine.- diagnosis of acpe was defined by the association of sudden onset of dyspnoea, the presence of bilateral rales on auscultation, respiratory rate \>25 breaths/min and pulse oxygen saturation \<90% in room air. diagnosis will be confirmed by echocardiography and lung ultrasound exclusion criteria: * patients with history of asthma, severe stenotic valvular disease. • cardiovascular collapse or an impaired level of consciousness (glasgow coma scale score of ≤8 points). immediate indication for intubation. • suspicion of st-segment elevation, acute coronary syndrome needing interventions. • known severe liver or renal disease, pneumonia, poor chance of survival due to a pre-existing condition. • psychiatric disorders.
evaluation of the information of the patient before a scheduled coronarography

Conditions: Cardiac Disease

Summary: french study, multicentrique with the cooperation of several hospital centers . 700 patients (200 in the stage 1 and 500 in the stage 2). every patient will complete questionnaires in a anonymous way.

stage 1: evaluation of the score in the population and the evaluation of the improvement of the score after an information more detailed by the educational video. for that purpose, inclusion on one week with comparison of the score obtained during a classic information with delivery of the sheet of information and during a classic information followed by an information more detailed with educational video. check during this stage of the significant improvement of the score with the addition of the educational video literally of information and in the oral information supplied usually within the framework of the current care evaluation of the number of subject included in the 1 week. stage 2: comparison of the patient understanding between 2 groups: 1 group received the information by using the information targeted with educational video (modern information) and the other group the classic information considered as the reference. inclusion planned over 2 weeks with for every center 1 week of classic information and 1 week of targeted information, allowing a randomized comparison of the 2 methods. to limit the biases of inclusions and the effect centers, every center will realize 1 week of every method, according to a specific drawing lots in every center to determine with which information (classic or targeted) the study will begin.

Eligibility criteria:
inclusion criteria: * hospitalisation for scheduled coronarography exclusion criteria: * coronarographies with general anesthesia. * patients not speaking or not reading french, or having linguistic knowledge not allowing the delivery of an appropriate information

Keywords: information coronarography understanding
a study of evorpacept (alx148) with venetoclax and azacitidine for acute myeloid leukemia (aspen-05)

Conditions: Acute Myeloid Leukemia; AML, Adult

Summary: this phase 1/2 clinical study will evaluate evorpacept (alx148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (aml).

the phase 1 will consist of a dose escalation of evorpacept (alx148) in combination with venetoclax and azacitidine to evaluate safety and tolerability, and to identify the recommended phase 2 dose of evorpacept (alx148) in combination with venetoclax and azacitidine. the phase 2 will evaluate the efficacy of evorpacept (alx148) in combination with venetoclax and azacitidine for patients with aml. while intended to be a phase 1/2 clinical study, the study never moved forward to phase 2.

Eligibility criteria:
inclusion criteria: * cytologically or histologically confirmed diagnosis of relapsed/refractory or newly diagnosed aml per who 2016 classification. * phase 1a: aml that is relapsed/refractory or that is previously untreated in patients not considered suitable for intensive induction therapy. * phase 1b: aml that is relapsed/refractory after prior treatment with a hma-based regimen. * phase 2: previously untreated aml in patients who are not considered suitable candidates for intensive induction therapy. * adequate renal and liver function. * age ≥18 years. * adequate performance status. exclusion criteria: * in phase 1a and 1b, patients that have undergone prior allo-hsct must be at least 3 months post-hsct, without uncontrolled graft-versus-host disease (gvhd). for phase 2, patients that have undergone prior allo-hsct are excluded. * patients with newly diagnosed aml with favorable risk cytogenetics such as t(8;21), inv(16), or t(16;16) as per the nccn guidelines version 3, 2019 for aml. * patients with acute promyelocytic leukemia (apl). * prior treatment with any anti-cd47 or anti-sirpalpha (signal regulatory protein alpha) agent. * known active viral infections, including hepatitis b and c, human immunodeficiency virus (hiv), acquired immunodeficiency syndrome (aids) related illness, or sars-cov-2 (severe acute respiratory syndrome coronavirus 2).

Keywords: alx148 cd47 sirpalpha azacitidine venetoclax evorpacept
angiogram based fractional flow reserve in patients with multi-vessel disease

Conditions: Multi Vessel Coronary Artery Disease

Summary: this is a prospective, observational, single-center, single-arm, clinical trial designed to assess the efficacy of ffrangio in measuring ffr obtained from angiography compared to invasive ffr for diagnosing hemodynamically significant coronary stenosis in multi-vessel disease.


Eligibility criteria:
inclusion criteria: * \>18 years of age. * patients with stable angina or unstable angina or nstemi, with at least 1 stenoses ≥ 50% in two main vessels (lad, lcx and/or rca) each and in whom invasive ffr is being assessed at these stenoses. * patients undergoing invasive ffr with adenosine, atp or papaverine used as hyperemic stimulus. * written, informed consent. exclusion criteria: * contraindication for ffr examination or administration of vasodilators. * clinical presentation of an acute infarct (stemi) or presented with stemi in past year. * cto in a target vessel. * prior cabg, valvular surgery, tavi/tavr, or heart transplantation. * known lvef ≤45%. * arteries supplying akinetic or severe hypokinetic territories if already known based on prior imaging. * timi grade 2 or lower at baseline. * target lesions involve left main (stenosis ≥50%.) * in-stent restenosis in a target vessel. * heavily diffused atherosclerosis diseases defined as the presence of diffuse, serial gross luminal irregularities present in the majority of the coronary tree. * target coronary vessels are supplied by major collaterals. * lesion is in ectatic segment which includes dilatation in diameter at least 1.5 times that of the adjacent normal coronary artery. * coronary angiograms not acquired per instructions as defined in the study protocol.
safety and initial feasibility of using the neurolyser for facet related low back pain

Conditions: Facet Related Low Back Pain

Summary: single arm pilot study to evaluate the safety and initial feasibility of the neurolyser xr, a new portable high intensity focused ultrasound device, for noninvasive thermal ablation of medial nerve branches of painful lumbar facet joint/s

study design: prospective, single arm timeline: six month enrollment period and 12 months follow-up period. sites: the study will be conducted at mcgill university. study population: ten adult patients diagnosed with facet related low back pain. primary study objective: safety and efficacy of the neurolyser xr for the treatment of facet related low back pain. safety would be evaluated by the incidence and severity of treatment related adverse events efficacy would be evaluated by the changes in average pain score and rolland morris disability questionnaire between baseline and 6 months.

Eligibility criteria:
inclusion criteria: 1. adult male and females, legally able and willing to participate in the study and come for follow-up visits 2. able and willing to fill the study forms and to communicate with investigator 3. patient with uni or bilateral lumbar facetogenic pain of \> 6 months duration 4. patients presenting with a) a positive (\>70% pain relief) to a previous l1 to l5 lumbar medial branch block and / or b) with a positive (\>70% pain relief) to a previous lumbar facet thermal rf denervation within the last 6 months) 5. average pain score of 4 or higher in the last month, (on a scale of 0 to 10) exclusion criteria: 1. pregnant or breastfeeding patient 2. patients younger than 18 or older than 80 years 3. patients presenting with neurological deficits (including lumbosacral radiculopathy but not radicular pain). 4. history of spine surgery 5. presence of metal hardware at the lumbosacral spine 6. lumbar spine pathology that may increase procedural risk and / or influence symptoms and / or generate unrelated adverse event, (per the discretion of the study pi) 7. patients unable to understand and complete the research questionnaires in english or french 8. any severe medical condition preventing the patient from safely and effectively being treated in the study or reporting study outcome. 9. patient with extensive scarring in the skin and tissue overlying the treatment area. 10. patients enrolled in or planned to be enrolled in another clinical trial during the duration of this research project
validation of the ntx wireless patient monitoring system

Conditions: Desaturation; Bradycardia; Tachycardia; Hypertension; Hypotension

Summary: * reduction in time to detection of clinically significant events * reduction of time to intervention during clinically significant events * reduction in the number of admissions to intensive care

1200 patients will have wireless monitors attached to their arm. they will be randomized to have their vital signs filtered through software that generates alerts, or software that does not generate alerts. low and high limit alarms will be set according to published guidelines and adjusted at will by the response team. if appropriate the vanderbilt university medical center rapid response team will be initiated per institutional policy

Eligibility criteria:
inclusion criteria: * ability to give written informed consent * patients that are hospitalized for longer than 24 hours and are located on the 4th, 5th, or 6th floor of the vanderbilt university medical center round wing * patients must be ≥18 years of age exclusion criteria: * icu patients * female subjects who are pregnant * patients \< 18 years of age * patients that have a contradiction for continuous blood pressure monitoring

Keywords: ntx nihon kohden mobile monitoring
neonatal mask seal; a two-handed versus one-handed approach: the neoseal study

Conditions: Neonatal Intensive Care

Summary: when babies can't breathe effectively, we can use a facemask to give them breaths and oxygen. the mask can be held with one or two hands, depending on the preference of the doctor. both types of mask holds are recommended in international guidelines, but it is unclear which one is better for the baby. if a lot of air is leaking around the mask, it means that the baby is not getting the full breathing support that the healthcare providers are trying to give. there currently is not enough evidence to say which type of hold is better to reduce this potential leaking of air. in this study, the investigators will compare two different ways of holding a mask on a baby's face to help them breathe. each baby will be randomly allocated to either a one-handed or a two-handed mask hold, and the investigators will measure how much air leaks out around the mask during each breath. any baby in the neonatal unit may be included in this study.

this study will compare the measured leak in mask ventilation delivered by a healthcare professional in the neonatal team, using a one-handed versus a two-handed hold with a standardised mask size and shape. this is to assess the two-handed technique as a potential first-line approach in neonatal bag-mask ventilation. the handholds will be assessed by a randomised controlled trial, with the two-handed hold as the intervention and the one-handed hold as the control. the population that will be studied is neonates in the neonatal intensive care unit (nicu), at any gestation, who the clinical team have decided to intubate. a member of the research team, who will provide an out-of-hours on call service, will attend the event. the relevant outcomes will be measured by the monivent neo100, which will be set up by the research team. standardised masks, as used per local protocol, will be used, with the sensor module placed between that and the t-piece with an adaptor. the outcomes will assess the effectiveness of both the intervention and control, including ventilation parameters recorded by the monivent neo100 and the clinical stability of the patient. the primary outcome of this study is the percentage mask leak. a research team member will record data for primary and secondary outcome. the event will be filmed for post-hoc video analysis. the outcome assessor will be blinded to the group allocation. this research project will take place over 24 months, with an interim analysis to ensure recruitment is projected to achieve sample size.

Eligibility criteria:
inclusion criteria: * all term and preterm neonates in the neonatal unit who the clinical team have decided to intubate, with or without pre-medication and who require mask ventilation prior to intubation attempt. exclusion criteria: * neonates with a congenital malformation that would impact mask seal will not be included.

Keywords: neonatology facemask ventilation face mask ventilation mask hold one-handed mask hold one-handed hold mask leak
examining an emergency room intervention for the prevention of post traumatic stress disorder (ptsd)

Conditions: Posttraumatic Stress Disorder

Summary: ptsd is a common and distressing possible outcome following exposure to a traumatic event. recent studies show that memory processes may be central to the development of the disorder, and interrupting the consolidation of traumatic memories may prevent the disorder from developing. specifically the use of a visual spatial task has been shown to reduce a key characteristic of ptsd, intrusions, in non-clinical populations. this study aims to administer a visual spatial task to recent trauma survivors in the emergency room, and compare ptsd and symptoms development in these patients as compared to a control group who did not carry out the task. the study hypothesizes that the task will result in less ptsd, lower levels of intrusions, dissociation and pain.


Eligibility criteria:
inclusion criteria: * age 18-65, * no loss of consciousness, * ability to understand study procedures and give informed consent, * hebrew as first language, * experienced a potentially traumatic event as defined in dsm (objective danger and subjective feeling of fear). exclusion criteria: * current or past psychiatric treatment, * current or past ptsd.

Keywords: ptsd prevention
a proof of concept and dose ranging study in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study is being carried out to investigate if azd5672 is effective in treating rheumatoid arthritis (ra) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already available to treat rheumatoid arthritis) when added to treatment with methotrexate. the purpose of this study is also to find out which dose of azd5672 is the most effective at treating ra and to find out how well the body tolerates azd5672 when taken for up to 12 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of ra with active disease defined as: ≥4 swollen joints and ≥6 tender/painful joints, and either have (blood tests) elevated erythrocyte sedimentation rate (esr) or c-reactive protein (crp). * at least one of the following: documented history of positive rheumatoid factor (blood test), current presence of positive rheumatoid factor (blood test), baseline radiographic erosion, presence of serum anti-cyclic citrullinated peptide antibodies (bloo * be receiving either: oral (tablets) or subcutaneous (injection) methotrexate for at least 6 months prior to randomisation. exclusion criteria: * any other inflammatory disease in addition to ra that may interfere with the study (e.g. polymyalgia rheumatica, giant cell arteritis, reactive arthritis, etc). * current chronic pain disorders including fibromyalgia and chronic fatigue syndromes.

Keywords: rheumatoid arthritis ra azd5672
measurement of a systolic pressure index at the toe after a walking test

Conditions: Good Health

Summary: the main objective of this study is to evaluate the concordance of the variation in systolic pressure indices measured at the toe and ankle after a walking test in healthy volunteers.

our secondary objectives are: * to evaluate the concordance between left- and right-side measures: systolic pressure indices measured at the toe after a walking test (healthy volunteers) * to evaluate the concordance between left- and right-side measures: systolic pressure indices measured at the ankle after a walking test (healthy volunteers) * to evaluate the concordance of the variation in systolic pressure indices measured at the toe and ankle during the recuperation phase after a walking test (5 and 10 minutes after end of walking test) in healthy volunteers

Eligibility criteria:
inclusion criteria: * the subject must have given his/her informed and signed consent * the subject must be insured or beneficiary of a health insurance plan exclusion criteria: * the subject is in an exclusion period determined by a previous study * the subject is under judicial protection, under tutorship or curatorship * the subject refuses to sign the consent * it is impossible to correctly inform the subject * the subject is pregnant, parturient, or breastfeeding * the subject has a contraindication for a walking test * presence of mediacalcose objectified by a doppler examination of the anterior and posterior tibial arteries, performed on the test day * known history of cardiovascular disease * poorly controlled diabetes or hypertension * neurological, muscular or rheumatic pathology contra-indicating a walking test * acute transient infection (cold-rhinitis, flu, etc.)

Keywords: blood pressure site good health brachial blood pressure ankle toe walking test exercise